Lappoxo

Omeprazole, the active ingredient in Lappoxo, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is prescribed for acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease, and for ulcer prevention in patients taking non‑steroidal anti‑inflammatory drugs.

GNH USA supplies Lappoxo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Omeprazole is used to treat conditions caused by excess gastric acid secretion.

Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining a higher gastric pH. Peptic ulcer disease: promotes healing of gastric and duodenal ulcers by reducing acid exposure. Helicobacter pylori eradication regimens: used as part of combination therapy to increase antibiotic effectiveness. Prevention of NSAID‑induced gastric ulcers: lowers ulcer risk in patients requiring long‑term non‑steroidal anti‑inflammatory drug therapy.

Omeprazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild, transient headache reported in some patients. - Diarrhea: loose stools or increased bowel movements. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis due to overgrowth of C. difficile. - Acute interstitial nephritis: sudden kidney inflammation presenting with rash and renal dysfunction. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use.

When prescribing omeprazole, clinicians should consider several safety and handling measures. - Assess renal function: dose adjustment may be required in severe renal impairment. - Monitor for infection: prolonged acid suppression can predispose to gastrointestinal infections. - Evaluate bone health: long‑term therapy may affect calcium absorption and bone density. - Review concomitant medications: potential interactions may necessitate timing adjustments. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Omeprazole can alter the pharmacokinetics of several drugs, requiring careful management.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: markedly decreased absorption, leading to therapeutic failure.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR closely. - Diazepam: increased plasma levels, observe for sedation. - Methotrexate (high dose): decreased renal clearance, monitor toxicity.